Sumitomo Pharma America Inc - Company Profile
Powered by 
All the sales intelligence you need on Sumitomo Pharma America Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sumitomo Pharma America Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sumitomo Pharma America Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sumitomo Pharma America Inc (SMPA), formerly Sunovion Pharmaceuticals Inc, is a research-based pharmaceutical company. It discovers, develops, and markets therapeutic products that focus on the treatment of the central nervous system and respiratory disorders. Its major products include eslicarbazepine acetate tablets, lurasidone HCl tablets, relugolix, estradiol, and norethindrone acetate tablets, vibegron tablets, relugolix tablets, and allogeneic processed thymus tissue–agdc. The company’s product candidates are intended for the treatment of schizophrenia, neuropathic pain, bipolar depression, treatment-resistant depression, agitation in Alzheimer's disease, and women’s healthcare products among others. It has partnerships with various pharmaceutical companies such as Psychogenics and others. SMPA is headquartered in Marlborough, Massachusetts, the US.
Headquarters
United States of America
Address
84 Waterford Drive, Marlborough, Massachusetts, 01752
Website
www.sunovion.com
Telephone
1 508 4816700
Industry
Pharmaceuticals and Healthcare
Sumitomo Pharma America Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Lurasidone HCi Tablets | DrugOME |
| Eslicarbazepine Acetate Tablets | Orgovyx |
| Vibegron Tablets | Gemtesa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In July, the company announced that the European Medicines Agency has granted orphan drug designation to Nuvisertib (TP-3654) for the treatment of myelofibrosis. |
| 2025 | Contracts/Agreements | In June, the company entered into an agreement with Knight Therapeutics, to commercialize Sumitomo’s Canadian portfolio. |
| 2025 | Regulatory Approval | In June, the company received US FDA fast-track designation for Nuvisertib (TP-3654), for the treatment of Myelofibrosis. |
Competitor Comparison
| Key Parameters | Sumitomo Pharma America Inc | Acadia Pharmaceuticals Inc | OptiNose Inc | Alexion Pharmaceuticals Inc | Curemark LLC |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Marlborough | San Diego | Yardley | Boston | Rye BrooK |
| State/Province | Massachusetts | California | Pennsylvania | Massachusetts | New York |
| No. of Employees | - | 796 | 127 | - | - |
| Entity Type | Private | Public | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Tsutomu Nakagawa, Ph.D. | President; Chief Executive Officer; Director | Executive Board | 2024 | - |
| Ron Gimbel | Chief Financial Officer; Director | Executive Board | 2023 | - |
| Yumi Sato | Chief Development Officer; Director | Executive Board | 2024 | - |
| Tara Soni | Chief Legal Officer | Senior Management | 2023 | - |
| Jatin Shah, M.D. | Chief Medical Officer - Oncology | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer